Simplified FOLFIRI in pre-treated patients with metastatic gastric cancer

Katia Lorizzo, Nicola Fazio, Davide Radice, Sabrina Boselli, Leonardo Ariu, Maria Giulia Zampino, Franco Nolè, Elena Magni, Raffaele Ardito, Ida Minchella, Andrea Rocca, Giovanni Di Meglio, Michela Squadroni, Filippo De Braud

Research output: Contribution to journalArticlepeer-review


Purpose: Second-line chemotherapy in patients with metastatic gastric cancer (MGC) pre-treated with cisplatin is not a standard option. We studied a combination of irinotecan, fluorouracil and folates. Methods: Patients progressive to cisplatin-based chemotherapy were enrolled. Irinotecan 180 mg/m 2, folinic acid 200 mg/m 2, and fluorouracil 400 mg/m 2 were given on day 1, immediately followed by fluorouracil 2,400 mg/m 2 46 h continuous infusion (simplified FOLFIRI), every 2 weeks. Results: Between June 2002 and May 2003, 28 patients were treated. Median age was 57 years (range 38-68). Most patients had a distal primary (90%), and metastatic disease (71%). Partial response was obtained in six patients (21%, 95% CI 8-41) and stable disease in eight (21%, 95% CI 13-41). Among the six responsive patients three were refractory to docetaxel. At a median follow-up of 2.9 years median time to progression was 4 months (95% CI: 2-5), and median overall survival was 5 months (95% CI 4-9). Toxicity was mild, without treatment-related deaths or life-treating adverse events. Conclusions: Simplified FOLFIRI was moderately active and well tolerated in unselected patients with MGC pre-treated with cisplatin-based chemotherapy. Its role in patients refractory to taxanes is promising and warrants further investigation.

Original languageEnglish
Pages (from-to)301-306
Number of pages6
JournalCancer Chemotherapy and Pharmacology
Issue number2
Publication statusPublished - Jul 2009


  • Irinotecan
  • Metastatic gastric cancer
  • Second line chemotherapy

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Pharmacology
  • Pharmacology (medical)
  • Toxicology


Dive into the research topics of 'Simplified FOLFIRI in pre-treated patients with metastatic gastric cancer'. Together they form a unique fingerprint.

Cite this